Trial Profile

A Phase 2, Open-label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Acceptability of Twice Yearly Long-acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in Cisgender Women in the United States

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lenacapavir (Primary) ; Lenacapavir (Primary)
Indications HIV infections
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Acronyms PURPOSE 3
Sponsors Gilead Sciences

19 Sep 2024 Planned End Date changed from 1 Jan 2028 to 1 Oct 2028.
19 Sep 2024 Planned primary completion date changed from 1 Jan 2028 to 1 Mar 2027.
02 May 2024 Planned End Date changed from 1 Jul 2027 to 1 Jan 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com